Cineverse Corp-A美股市值招股说明书(2025-07-11版)

entered into as of May 3, 2024 (the “Sales Agreement”) with the Agents. This supplement should be read in conjunction with, is not completewithout, and may not be delivered or utilized except in connection with, the initial prospectus supplement, including all supplements thereto anddocuments incorporated by reference therein. If there is any inconsistency between the information in the initial prospectus supplement and thissupplement, you should rely on the information in this supplement. Any information that is modified or superseded in the initial prospectussupplement shall not be deemed to constitute a part of the initial prospectus supplement, except as modified or superseded by this supplement.The sales agreement with the Agents provides that we may issue and sell shares of our Common Stock registered on the Registration Statementfrom time to time to or through the Agents subject to offering limitations, as applicable, under General Instruction I.B.6. of Form S-3. As of thefiling of this prospectus supplement, such offering limitations were not applicable. sales agreement, we may offer and sell through the initial prospectus supplement, as amended and supplemented by supplement no. 1 and thissupplement no. 2, shares of Common Stock having an aggregate offering price of up to $15,000,000 from time to time to or through the Agents.This supplement no. 2 is being filed to update this position, previously reported in supplement no. 1, after the filing of our Annual Report on Form initial prospectus supplement.The shares of our Common Stock are listed for trading on The Nasdaq Capital Market (“Nasdaq”) under the symbol “CNVS.” On July 10, 2025,the last reported sale price of the Common Stock on Nasdaq was $6.82 per share.Investing in our securities involves significant risks. See “Risk Factors” in the initial prospectus supplement, and under similar headings inother documents filed and incorporated by reference herein and therein for a discussion of factors that you should consider before buying passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.A.G.P.The Benchmark Company The date of this supplement is July 11, 2025.